← Back to Search

Patient portal for Flu Vaccine

N/A
Waitlist Available
Led By Christopher Chabris, PhD
Research Sponsored by Geisinger Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Included on a list of active Geisinger patients (all patients on this list attended at least one primary care appointment at Geisinger between 10/1/2008 and 4/13/2022, and either had a Geisinger primary care provider assigned as of April 2022, or were in the Electronic Health Record [EHR] since at least September 2021 and had at least one encounter in 2020-2022)
Aged 18 or older
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 11 months
Awards & highlights

Study Summary

This trial is testing which method of communication is most effective in getting high-risk patients to get a flu shot.

Eligible Conditions
  • Flu Vaccine
  • Health Promotion
  • Health Behaviors
  • Risk Reduction

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 11 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 11 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Flu vaccination
Other outcome measures
"Likely flu" diagnosis
COVID-19 vaccination rates
ER visits
+3 more

Trial Design

6Treatment groups
Experimental Treatment
Active Control
Group I: SMS onlyExperimental Treatment1 Intervention
This group will receive an SMS telling them they are at high risk for flu and complications
Group II: Patient portal onlyExperimental Treatment1 Intervention
This group will receive a patient portal message telling them they are at high risk for flu and complications
Group III: Patient portal + SMSExperimental Treatment2 Interventions
This group will receive a patient portal message and an SMS telling them they are at high risk for flu and complications
Group IV: Letter onlyExperimental Treatment1 Intervention
This group will receive a letter telling them they are at high risk for flu and complications
Group V: Letter + Patient portal + SMSExperimental Treatment3 Interventions
This group will receive a letter, a patient portal message, and an SMS telling them they are at high risk for flu and complications
Group VI: ControlActive Control1 Intervention
No additional pro-vaccination intervention - some patients are currently targeted for flu vaccination messages due to a non-machine learning-based assessment that they are at high risk for complications, but are not told that they are at high risk or that they have been targeted
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Letter
2020
N/A
~137510
Patient portal
2022
N/A
~43230
SMS
2016
N/A
~59160

Find a Location

Who is running the clinical trial?

Geisinger ClinicLead Sponsor
148 Previous Clinical Trials
1,842,868 Total Patients Enrolled
Christopher Chabris, PhDPrincipal InvestigatorGeisinger Clinic
4 Previous Clinical Trials
309,057 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Efficacy of Communication Modalities for Promoting Flu Shots
Christopher F Chabris, PhD 2022. "Efficacy of Communication Modalities for Promoting Flu Shots". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05509270.
~16732 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top